Synonyms: | |
Status: | Phase 3 |
Entry Type: | Antibody |
Molecule Category: | UNKNOWN |
UNII: | U59UGK3IPC |
Action | Mechanism of Action | Reference |
---|---|---|
BINDING AGENT | B-lymphocyte antigen CD20 binding agent | PubMed |
Primary Target | |
---|---|
CD20 (membrane-spanning 4-domains, subfamily A, member 1) |
Mesh Heading | Maximum Phase | Mesh ID | Reference |
---|---|---|---|
Leukemia, Lymphocytic, Chronic, B-Cell | 3 | D015451 | ClinicalTrials |
Multiple Sclerosis | 3 | D009103 | ClinicalTrials |
Multiple Sclerosis, Relapsing-Remitting | 2 | D020529 | ClinicalTrials |
Lymphoma, Mantle-Cell | 2 | D020522 | ClinicalTrials |
Lymphoma, Follicular | 2 | D008224 | ClinicalTrials |
Lymphoma, Large B-Cell, Diffuse | 2 | D016403 | ClinicalTrials |
Lymphoma, Follicular | 2 | D008224 | ClinicalTrials |
Neuromyelitis Optica | 1 | D009471 | ClinicalTrials |
Waldenstrom Macroglobulinemia | 1 | D008258 | ClinicalTrials |
Resources | Reference |
---|---|
CAS NUMBER | 1174014-05-1 |
ChEMBL | CHEMBL2108354 |
FDA SRS | U59UGK3IPC |
Guide to Pharmacology | 8920 |